Abstract
The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Current Genomics
Title: Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Volume: 5 Issue: 3
Author(s): D. Roy and K. P. Singh
Affiliation:
Keywords: estrogen, reactive oxygen (nitrogen) species, genetic alterations, carcinogenicity
Abstract: The oxidation of catechol metabolites (2-OH-E1 / 2 / 3 and 4-OH-E1 / 2 / 3) of the endogenous estrogen, i.e. estrone (E1), 17 beta-estradiol (E2), estriol (E3), gives rise to corresponding estrogen-2,3-quinone (E-2,3-Q) and estrogen-3,4- quinone (E-3,4-Q). These reactive estrogen metabolites form covalent adducts with DNA and quinone, and semi-quinone forms of catechol estrogens -induced DNA adducts are found in various target tissues of cancer. Catecholestrogen through redox cycling produce free radicals that also generate various forms of free radical-induced DNA damage. Interaction of estrogen-induced oxidants and estrogen metabolites with DNA has been shown to generate mutations in genes. Hypermethylation at CpG sites in specific regions of the genome coupled with estrogen-induced oxidative damage at CpG sites, predominantly in the hypermethylated regions, could also cause alterations in the genome of cells of estrogen target organs that lead to mutation of genes. Increasing evidence shows that estrogen through oxidative stress and / or its metabolic products induce genetic alteration affecting both the structural as well as function of the genes. Presence of multiple forms of genetic alterations such as chromosomal aberrations, gene amplifications, DNA sequence variations, and DNA microsatellite instability in estrogen-related cancers and induction of similar genetic events by estrogen both in vivo and in vitro indicate that genetic alterations play an important role in estrogen-related carcinogenesis. This review highlights the current understanding of the estrogen-induced genetic alterations and their significance in estrogen-related carcinogenesis.
Export Options
About this article
Cite this article as:
Roy D. and Singh P. K., Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349471
DOI https://dx.doi.org/10.2174/1389202043349471 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Genomic Insights into Oncology: Harnessing Machine Learning for Breakthroughs in Cancer Genomics.
This special issue aims to explore the cutting-edge intersection of genomics and oncology, with a strong emphasis on original data and experimental validation. While maintaining the focus on how machine learning and advanced data analysis techniques are revolutionizing our understanding and treatment of cancer, this issue will prioritize contributions that ...read more
Integrating Artificial Intelligence and Omics Approaches in Complex Diseases
Recent advancements in AI and omics methodologies have revolutionized the landscape of biomedical research, enabling us to extract valuable information from vast amounts of complex data. By combining AI algorithms with omics technologies such as genomics, proteomics, metabolomics, and transcriptomics, researchers can obtain a more comprehensive and multi-dimensional analysis of ...read more
Integrating Machine Learning with Genome Science: Pioneering Developments and Future Directions
Integrating machine learning (ML) with genome science is driving transformative advancements in fields such as genomics, personalized medicine, and drug discovery. Genomic data is vast and complex, making traditional analysis methods inadequate for uncovering deep insights. Machine learning, particularly deep learning models like convolutional neural networks (CNNs) and recurrent neural ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Development of Genetic Testing for Breast, Ovarian and Colorectal Cancer Predisposition: A Step Closer to Targeted Cancer Prevention
Current Drug Targets From Natural Products to Designer Drugs: Development and Molecular Mechanisms Action of Novel Anti-Microtubule Breast Cancer Therapeutics
Current Topics in Medicinal Chemistry Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro
Current Drug Delivery Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Chitosan Nano-encapsulation Enhances Gedunin Cytotoxicity A gainst Human Non-small-cell Lung Cancer (NCI-H292) Cell Line
Drug Delivery Letters Garlic (<i>Allium sativum</i> L.): Its Chemistry, Nutritional Composition, Toxicity, and Anticancer Properties
Current Topics in Medicinal Chemistry Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets IMPDH2 Positively Impacts the Proliferation Potential of Hepatoblastoma Cells by Activating JunB Signaling Pathway
Current Molecular Pharmacology Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets